Translational Oncology

Scope & Guideline

Shaping the Future of Oncology Through Discovery

Introduction

Welcome to your portal for understanding Translational Oncology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1936-5233
PublisherELSEVIER SCIENCE INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2008 to 2024
AbbreviationTRANSL ONCOL / Transl. Oncol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

Translational Oncology focuses on bridging the gap between laboratory research and clinical application in oncology. It aims to publish high-quality research that provides insights into various cancer mechanisms, treatment strategies, and patient care improvements.
  1. Innovative Cancer Therapies:
    The journal emphasizes the development and evaluation of new treatment modalities, including immunotherapy, targeted therapies, and combination regimens, to improve patient outcomes.
  2. Genomic and Molecular Insights:
    Research articles often explore the molecular and genetic underpinnings of various cancers, aiming to identify biomarkers for diagnosis, prognosis, and treatment response.
  3. Patient-Centric Research:
    A focus on clinical outcomes, quality of life, and patient management strategies, including studies on the impact of therapies on patient well-being and treatment adherence.
  4. Translational Research Methodologies:
    The journal publishes studies employing diverse approaches such as machine learning, bioinformatics, and real-world evidence to enhance translational research in oncology.
  5. Multidisciplinary Approaches:
    Translational Oncology supports research that integrates various disciplines, including surgery, radiation therapy, and medical oncology, to optimize cancer treatment.
Translational Oncology is witnessing a rise in various emerging themes that reflect the evolving landscape of cancer research and treatment.
  1. Immunotherapy and Combination Treatments:
    There is a marked increase in research focused on immuno-oncology, especially studies exploring combination therapies that leverage immune checkpoint inhibitors alongside traditional treatments.
  2. Precision Medicine and Genomics:
    An emerging trend is the emphasis on precision medicine, with studies investigating genomic profiling to tailor treatments to individual patient needs and enhance therapeutic efficacy.
  3. Microbiome and Cancer Interactions:
    Research exploring the role of the microbiome in cancer progression and treatment response is gaining traction, highlighting the complex interactions between gut health and oncology.
  4. Artificial Intelligence and Machine Learning Applications:
    The adoption of AI and machine learning techniques to predict treatment responses and outcomes is a growing area of interest, showcasing the integration of technology in cancer research.
  5. Patient-Reported Outcomes and Quality of Life:
    There is an increasing focus on understanding patient-reported outcomes, emphasizing the importance of quality of life in treatment evaluations and clinical trial designs.

Declining or Waning

While Translational Oncology continues to expand in several areas, certain themes have seen a decline in focus over recent years, signaling shifts in research priorities.
  1. Traditional Chemotherapy Studies:
    Research on conventional chemotherapy regimens is less frequent as newer targeted therapies and immunotherapies gain prominence, reflecting a shift towards more personalized treatment strategies.
  2. Basic Laboratory Studies:
    There is a noticeable reduction in purely laboratory-based studies that do not translate into clinical applications, as the journal increasingly prioritizes translational and clinical research.
  3. Single-Agent Studies:
    Publications focusing solely on the efficacy of single-agent therapies are declining, as combination therapies and multi-modal approaches are favored in the current oncological landscape.
  4. Epidemiological Studies:
    While important, traditional epidemiological studies are becoming less emphasized in favor of research that integrates clinical outcomes and translational insights.
  5. Local Treatment Modalities:
    Research centered on localized treatment methods, such as conventional surgery alone, is waning as the field moves towards more comprehensive, systemic treatment paradigms.

Similar Journals

Molecular and Clinical Oncology

Transforming insights into impactful oncology practices.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9450Frequency: 12 issues/year

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Cancer Research Communications

Advancing the frontiers of cancer knowledge.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Targeted Oncology

Pioneering the path to targeted cancer therapies.
Publisher: SPRINGERISSN: 1776-2596Frequency: 6 issues/year

Targeted Oncology is a premier, peer-reviewed journal published by SPRINGER, focusing on the latest advancements in the field of oncology, specifically targeting the development and application of targeted therapies. Since its inception in 2006, this journal has become an essential resource for researchers, healthcare professionals, and students, providing critical insights into innovative cancer treatments and the pharmacological landscape. Recognized for its impactful contributions, Targeted Oncology holds a distinguished Q1 ranking in both Oncology and Pharmacology categories as of 2023, underscoring its influence and relevance in the scientific community. With an impressive Scopus ranking reflecting its strong citation impact, the journal not only disseminates high-quality research but also facilitates knowledge exchange among oncologists and researchers working towards improving patient outcomes. Although not an Open Access journal, Targeted Oncology is committed to advancing cancer research and therapeutic strategies, making it an invaluable addition to the libraries of any institution dedicated to health and wellness.

Oncology Reviews

Advancing the Frontier of Cancer Research
Publisher: FRONTIERS MEDIA SAISSN: 1970-5557Frequency: 2 issues/year

Oncology Reviews, founded in 2007 and published by FRONTIERS MEDIA SA, is a leading open-access journal dedicated to advancing knowledge in the field of oncology and cancer research. With an Impact Factor reflecting its robust engagement in scholarly discourse, this journal maintains a prestigious standing, earning a Q2 ranking in Oncology and a Q3 ranking in Cancer Research as of 2023. Notably, it is indexed in Scopus, where it ranks #118 in Oncology and #98 in Cancer Research, highlighting its global reach and significance. The journal's open-access policy, in effect since 2012, ensures that high-quality research is accessible to all, fostering collaboration and wellness improvements worldwide. This commitment to accessibility and dissemination of pivotal research makes Oncology Reviews an essential resource for researchers, healthcare professionals, and students eager to contribute to and stay abreast of the latest innovations in cancer treatment and research.

World Journal of Gastrointestinal Oncology

Connecting research and practice in gastrointestinal health and cancer.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

INTERNATIONAL JOURNAL OF CANCER

Transforming knowledge into breakthroughs in cancer care.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.

ONCOLOGY RESEARCH

Empowering Researchers to Transform Oncology
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

World Journal of Clinical Oncology

Empowering Oncology with Cutting-Edge Insights
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.

Journal of Cancer Metastasis and Treatment

Pioneering insights into cancer metastasis and treatment.
Publisher: OAE PUBLISHING INCISSN: 2394-4722Frequency: 1 issue/year

Journal of Cancer Metastasis and Treatment, published by OAE PUBLISHING INC, stands as a vital resource in the field of oncology, focusing on advancements and research pertaining to cancer metastasis and treatment methodologies. With an ISSN of 2394-4722 and an E-ISSN of 2454-2857, this journal aims to serve as a comprehensive platform for sharing innovative research, critical analyses, and novel findings from 2019 through 2024. As indexed in Scopus, it holds a notable Q3 ranking within its category, positioned at 240/404 and within the 40th percentile, thus reflecting its growing significance in the scientific community. Though currently not open access, the journal aspires to improve accessibility to pivotal oncology research, making it an essential tool for researchers, clinicians, and students keen on unraveling the complexities of cancer treatment and metastasis. Its commitment to promoting high-quality studies plays a crucial role in the ongoing quest to enhance patient care and outcomes in cancer treatment.

Hepatoma Research

Exploring New Horizons in Hepatoma Studies
Publisher: OAE PUBLISHING INCISSN: 2394-5079Frequency: 1 issue/year

Hepatoma Research is a pivotal academic journal dedicated to advancing the field of hepatology and oncology, published by OAE PUBLISHING INC. Launched in 2019, this open-access journal has quickly established itself as a valuable resource for researchers and professionals dedicated to the study of liver cancer and related disorders. With an ISSN of 2394-5079 and E-ISSN 2454-2520, it offers insightful research articles and reviews aimed at enhancing clinical practices and understanding the complexities surrounding hepatoma. The journal is ranked in the Q3 category for both hepatology and oncology as of 2023, reflecting its commitment to quality amidst a competitive landscape. With its Scopus rankings placing it at the 47th percentile in hepatology and the 39th percentile in oncology, Hepatoma Research continues to be a crucial platform for disseminating groundbreaking findings. This journal underscores the importance of collaborative research and encourages submissions that contribute to the global discourse on liver cancer treatment and management.